Pay in 4 interest-free payments of $7.28 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Orforglipron, a non-peptide GLP-1 receptor agonist, represents another daily oral incretin-based AOM displaying dose-dependent BW and WC reductions at 36 weeks ranging from 9.4 to 14.7% and from 9.6 cm to 13.6 cm with the 12 and 45 mg dose, respectively, in mostly female (59%) patients with a mean age of 54.2 years and BMI 37.9 kg/m 2 44
Concentration-to-dose conversion ensures you and your provider speak the same language about your treatment
That process takes years, not months
Without behavior change, weight comes back
If you're seeking a modern, patient-first approach to weight management, visit the official Brello Health website to explore its programs, eligibility requirements, and GLP-1 treatment options
